Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programsEnd-to-end supply chain combines 4basebio's proprietary opDNA® enzymatic DNA starting material with TriLink's industry-leading GMP mRNA manufacturing capabilities and proprietary CleanCap® co-transcriptional capping technology CAMBRIDGE, UK – 28 September, 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade o ...